Evidence map›Paper›PMID 34616490›Full record

ArticleTherapeutic advances in medical oncology2021

Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.

Moritz Müller, Florian Posch, Dominik Kiem, Dominik Barth, Lena Horvath, Michael Stotz, Renate Schaberl-Moser, Martin Pichler, Richard Greil, Philipp J Jost and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Moritz MüllerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Florian PoschDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Dominik KiemIIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria.
Dominik BarthDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Lena HorvathDepartment of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Michael StotzDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Renate Schaberl-MoserDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Martin PichlerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Richard GreilIIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria.
Philipp J JostDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Andreas SeeberDepartment of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Arno AmannDepartment of Internal Medicine V: Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Konstantin SchlickIIIrd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria.
Armin GergerDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Jakob M RiedlDivision of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, Graz 8036, Austria.
Medical University of Graz · ATParacelsus Medical University · ATUniversität Innsbruck · ATInnsbruck Medical University · ATTechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC)

methodsWe conducted a tri-center retrospective cohort study (

resultsThe most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35-0.69,

conclusionThis real-world study supports the concept that systemic second-line therapy prolongs survival in patients with aESCC.

Indexed as

best supportive careoesophageal cancerpalliative treatmentreal-world studysecond line therapy

Identifiers

PMID34616490
PMCPMC8488508
OpenAlexW3203205368

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.